Type i interferon limits interleukin-6 signalling in SLE through shedding interleukin-6 receptors

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Martyna Hempel - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Erik Klapproth - , Institute of Pharmacology and Toxicology (Author)
  • Annika Krause - , University of Münster (Author)
  • Christoph Becker-Pauly - , Kiel University (Author)
  • Sebastian Zeissig - , Department of Internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Babett Heschel - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Nadine Weser - , Institute of Pharmacology and Toxicology (Author)
  • Julia Fantana - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Nicolai Leuchten - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Stefan Rose-John - , Department of internal Medicine I, University Hospital Carl Gustav Carus Dresden (Author)
  • Ali El-Armouche - , Institute of Pharmacology and Toxicology (Author)
  • Adelheid Korb-Pap - , University of Münster (Author)
  • Martin Aringer - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)

Abstract

Objective To fully understand why C-reactive protein (CRP) is usually only mildly elevated in active systemic lupus erythematosus (SLE), although interleukin-6 (IL-6) is increased, but is high in SLE patients with bacterial infections. Methods Sera and peripheral blood mononuclear cells (PBMCs) of SLE patients and healthy individuals were investigated. IL-6 and soluble IL-6 receptor (sIL-6R) were measured by ELISA. Membrane IL-6 receptor-α (CD126), gp130 (CD130) and signal transducer and activator of transcription 3 (STAT3) phosphorylation after IL-6 stimulation were analysed by flow cytometry. PBMCs and HepG2 liver cells were stimulated with various cytokines, and IL-6 receptor shedding was determined by immunoprecipitation and western blotting of supernatants. HEK-293 T cells were transfected with wild type CD126 or a shedding-resistant mutant, and soluble sIL-6R was measured following cytokine stimulation. Results While sIL-6R and IL-6 were increased with SLE activity, CD126 positive lymphocytes were decreased in SLE. IL-6 plus IFNα decreased CD126 on lymphocytes, but increased sIL-6R in their supernatant, detected by immunoprecipitation and western blotting. IL-6 plus IFNα on HepG2 liver cells resulted in a similar sIL-6R increase. Increased supernatant sIL-6R was seen in HEK-293 T cells transfected with wild type CD126, but not those transfected with the shedding-resistant mutant. STAT3 phosphorylation upon IL-6 stimulation was reduced. Conclusion The combination of IL-6 and type I IFN induces shedding of CD126 to sIL-6R, shifting IL-6 signalling to trans-signalling. In situations of IL-6 excess over sIL-6R only, IL-6 or IL-6-sIL-6R complexes reach the liver and increase CRP. These findings not only explain the discrepancy in SLE, but also have implications for severe viral infection.

Details

Original languageEnglish
Pages (from-to)5793-5802
Number of pages10
JournalRheumatology
Volume64
Issue number11
Publication statusPublished - 1 Nov 2025
Peer-reviewedYes

External IDs

PubMed 40632603
ORCID /0000-0002-9348-5259/work/199962106
ORCID /0000-0003-2514-9429/work/199962584
ORCID /0000-0003-4471-8375/work/199962786

Keywords

ASJC Scopus subject areas

Keywords

  • disease activity, interleukin-6, lupus, receptor shedding, trans-signalling, type I interferon